创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

FDA警告信给中国药品生产企业的启示

Enlightenment of FDA Warning Letter to Chinese Drug Manufacturers

  • 摘要: 通过对美国食品药品监督管理局(FDA)官网2019年1月—2023年12月警告信数据库进行检索,从FDA检查地理分布及趋势、发给中国企业警告信缺陷项统计等多维度进行整理分析,提出思考与建议,希望为我国药品生产企业接受FDA检查提供相应的经验与启示,做到把握检查趋势,关注检查重点,为我国药品走向国际市场打好基础。

     

    Abstract: Through searching the warning letter database of the US Food and Drug Administration (FDA) official website from January 2019 to December 2023, this paper sorts out and analyzes the geographical distribution and trend, and the statistics of warning letter defects issued to Chinese enterprises, putting forward some thoughts and suggestions, in the hope of providing corresponding experience and enlightenment for China's drug manufacturers to pass FDA inspection, grasping the inspection trend, paying attention to the inspection focus, and laying a good foundation for China's drugs to enter the international market.

     

/

返回文章
返回